Molecular Cytogenetics Market By Product, By Technique, By Application, By End User: Global Opportunity Analysis and Industry Forecast, 2021-2031

Table of Contents

CHAPTER 1: INTRODUCTION
1.1. Report description
1.2. Key market segments
1.3. Key benefits to the stakeholders
1.4. Research Methodology
1.4.1. Secondary research
1.4.2. Primary research
1.4.3. Analyst tools and models

CHAPTER 2: EXECUTIVE SUMMARY
2.1. Key findings of the study
2.2. CXO Perspective

CHAPTER 3: MARKET OVERVIEW
3.1. Market definition and scope
3.2. Key findings
3.2.1. Top investment pockets
3.3. Porter’s five forces analysis
3.4. Top player positioning
3.5. Market dynamics
3.5.1. Drivers
3.5.2. Restraints
3.5.3. Opportunities
3.6. COVID-19 Impact Analysis on the market
3.7. Patent Landscape

CHAPTER 4: MOLECULAR CYTOGENETICS MARKET, BY PRODUCT
4.1 Overview
4.1.1 Market size and forecast
4.2 Instruments
4.2.1 Key market trends, growth factors and opportunities
4.2.2 Market size and forecast, by region
4.2.3 Market analysis by country
4.3 Consumables
4.3.1 Key market trends, growth factors and opportunities
4.3.2 Market size and forecast, by region
4.3.3 Market analysis by country
4.4 Software and Services
4.4.1 Key market trends, growth factors and opportunities
4.4.2 Market size and forecast, by region
4.4.3 Market analysis by country

CHAPTER 5: MOLECULAR CYTOGENETICS MARKET, BY TECHNIQUE
5.1 Overview
5.1.1 Market size and forecast
5.2 Comparative Genomic Hybridization
5.2.1 Key market trends, growth factors and opportunities
5.2.2 Market size and forecast, by region
5.2.3 Market analysis by country
5.2.4 Comparative Genomic Hybridization Molecular Cytogenetics Market by Type
5.2.4.1 Array-Based Comparative Genomic Hybridization Market size and forecast, by region
5.2.4.2 Standard Comparative Genomic Hybridization Market size and forecast, by region
5.3 Fluorescence in Situ Hybridization
5.3.1 Key market trends, growth factors and opportunities
5.3.2 Market size and forecast, by region
5.3.3 Market analysis by country
5.4 Others
5.4.1 Key market trends, growth factors and opportunities
5.4.2 Market size and forecast, by region
5.4.3 Market analysis by country

CHAPTER 6: MOLECULAR CYTOGENETICS MARKET, BY APPLICATION
6.1 Overview
6.1.1 Market size and forecast
6.2 Genetic Disorders
6.2.1 Key market trends, growth factors and opportunities
6.2.2 Market size and forecast, by region
6.2.3 Market analysis by country
6.3 Cancer
6.3.1 Key market trends, growth factors and opportunities
6.3.2 Market size and forecast, by region
6.3.3 Market analysis by country
6.4 Personalized Medicines
6.4.1 Key market trends, growth factors and opportunities
6.4.2 Market size and forecast, by region
6.4.3 Market analysis by country
6.5 Others
6.5.1 Key market trends, growth factors and opportunities
6.5.2 Market size and forecast, by region
6.5.3 Market analysis by country

CHAPTER 7: MOLECULAR CYTOGENETICS MARKET, BY END USER
7.1 Overview
7.1.1 Market size and forecast
7.2 Clinical and Research Laboratories
7.2.1 Key market trends, growth factors and opportunities
7.2.2 Market size and forecast, by region
7.2.3 Market analysis by country
7.3 Pharmaceutical and Biotechnology Companies
7.3.1 Key market trends, growth factors and opportunities
7.3.2 Market size and forecast, by region
7.3.3 Market analysis by country
7.4 Others
7.4.1 Key market trends, growth factors and opportunities
7.4.2 Market size and forecast, by region
7.4.3 Market analysis by country

CHAPTER 8: MOLECULAR CYTOGENETICS MARKET, BY REGION
8.1 Overview
8.1.1 Market size and forecast
8.2 North America
8.2.1 Key trends and opportunities
8.2.2 North America Market size and forecast, by Product
8.2.3 North America Market size and forecast, by Technique
8.2.3.1 North America Comparative Genomic Hybridization Molecular Cytogenetics Market by Type
8.2.4 North America Market size and forecast, by Application
8.2.5 North America Market size and forecast, by End User
8.2.6 North America Market size and forecast, by country
8.2.6.1 U. S.
8.2.6.1.1 Market size and forecast, by Product
8.2.6.1.2 Market size and forecast, by Technique
8.2.6.1.3 Market size and forecast, by Application
8.2.6.1.4 Market size and forecast, by End User
8.2.6.2 Canada
8.2.6.2.1 Market size and forecast, by Product
8.2.6.2.2 Market size and forecast, by Technique
8.2.6.2.3 Market size and forecast, by Application
8.2.6.2.4 Market size and forecast, by End User
8.2.6.3 Mexico
8.2.6.3.1 Market size and forecast, by Product
8.2.6.3.2 Market size and forecast, by Technique
8.2.6.3.3 Market size and forecast, by Application
8.2.6.3.4 Market size and forecast, by End User
8.3 Europe
8.3.1 Key trends and opportunities
8.3.2 Europe Market size and forecast, by Product
8.3.3 Europe Market size and forecast, by Technique
8.3.3.1 Europe Comparative Genomic Hybridization Molecular Cytogenetics Market by Type
8.3.4 Europe Market size and forecast, by Application
8.3.5 Europe Market size and forecast, by End User
8.3.6 Europe Market size and forecast, by country
8.3.6.1 Germany
8.3.6.1.1 Market size and forecast, by Product
8.3.6.1.2 Market size and forecast, by Technique
8.3.6.1.3 Market size and forecast, by Application
8.3.6.1.4 Market size and forecast, by End User
8.3.6.2 France
8.3.6.2.1 Market size and forecast, by Product
8.3.6.2.2 Market size and forecast, by Technique
8.3.6.2.3 Market size and forecast, by Application
8.3.6.2.4 Market size and forecast, by End User
8.3.6.3 UK
8.3.6.3.1 Market size and forecast, by Product
8.3.6.3.2 Market size and forecast, by Technique
8.3.6.3.3 Market size and forecast, by Application
8.3.6.3.4 Market size and forecast, by End User
8.3.6.4 Italy
8.3.6.4.1 Market size and forecast, by Product
8.3.6.4.2 Market size and forecast, by Technique
8.3.6.4.3 Market size and forecast, by Application
8.3.6.4.4 Market size and forecast, by End User
8.3.6.5 Spain
8.3.6.5.1 Market size and forecast, by Product
8.3.6.5.2 Market size and forecast, by Technique
8.3.6.5.3 Market size and forecast, by Application
8.3.6.5.4 Market size and forecast, by End User
8.3.6.6 Rest of Europe
8.3.6.6.1 Market size and forecast, by Product
8.3.6.6.2 Market size and forecast, by Technique
8.3.6.6.3 Market size and forecast, by Application
8.3.6.6.4 Market size and forecast, by End User
8.4 Asia-Pacific
8.4.1 Key trends and opportunities
8.4.2 Asia-Pacific Market size and forecast, by Product
8.4.3 Asia-Pacific Market size and forecast, by Technique
8.4.3.1 Asia-Pacific Comparative Genomic Hybridization Molecular Cytogenetics Market by Type
8.4.4 Asia-Pacific Market size and forecast, by Application
8.4.5 Asia-Pacific Market size and forecast, by End User
8.4.6 Asia-Pacific Market size and forecast, by country
8.4.6.1 Japan
8.4.6.1.1 Market size and forecast, by Product
8.4.6.1.2 Market size and forecast, by Technique
8.4.6.1.3 Market size and forecast, by Application
8.4.6.1.4 Market size and forecast, by End User
8.4.6.2 China
8.4.6.2.1 Market size and forecast, by Product
8.4.6.2.2 Market size and forecast, by Technique
8.4.6.2.3 Market size and forecast, by Application
8.4.6.2.4 Market size and forecast, by End User
8.4.6.3 Australia
8.4.6.3.1 Market size and forecast, by Product
8.4.6.3.2 Market size and forecast, by Technique
8.4.6.3.3 Market size and forecast, by Application
8.4.6.3.4 Market size and forecast, by End User
8.4.6.4 India
8.4.6.4.1 Market size and forecast, by Product
8.4.6.4.2 Market size and forecast, by Technique
8.4.6.4.3 Market size and forecast, by Application
8.4.6.4.4 Market size and forecast, by End User
8.4.6.5 South Korea
8.4.6.5.1 Market size and forecast, by Product
8.4.6.5.2 Market size and forecast, by Technique
8.4.6.5.3 Market size and forecast, by Application
8.4.6.5.4 Market size and forecast, by End User
8.4.6.6 Rest of Asia-Pacific
8.4.6.6.1 Market size and forecast, by Product
8.4.6.6.2 Market size and forecast, by Technique
8.4.6.6.3 Market size and forecast, by Application
8.4.6.6.4 Market size and forecast, by End User
8.5 LAMEA
8.5.1 Key trends and opportunities
8.5.2 LAMEA Market size and forecast, by Product
8.5.3 LAMEA Market size and forecast, by Technique
8.5.3.1 LAMEA Comparative Genomic Hybridization Molecular Cytogenetics Market by Type
8.5.4 LAMEA Market size and forecast, by Application
8.5.5 LAMEA Market size and forecast, by End User
8.5.6 LAMEA Market size and forecast, by country
8.5.6.1 Brazil
8.5.6.1.1 Market size and forecast, by Product
8.5.6.1.2 Market size and forecast, by Technique
8.5.6.1.3 Market size and forecast, by Application
8.5.6.1.4 Market size and forecast, by End User
8.5.6.2 Saudi Arabia
8.5.6.2.1 Market size and forecast, by Product
8.5.6.2.2 Market size and forecast, by Technique
8.5.6.2.3 Market size and forecast, by Application
8.5.6.2.4 Market size and forecast, by End User
8.5.6.3 South Africa
8.5.6.3.1 Market size and forecast, by Product
8.5.6.3.2 Market size and forecast, by Technique
8.5.6.3.3 Market size and forecast, by Application
8.5.6.3.4 Market size and forecast, by End User
8.5.6.4 Rest of LAMEA
8.5.6.4.1 Market size and forecast, by Product
8.5.6.4.2 Market size and forecast, by Technique
8.5.6.4.3 Market size and forecast, by Application
8.5.6.4.4 Market size and forecast, by End User

CHAPTER 9: COMPANY LANDSCAPE
9.1. Introduction
9.2. Top winning strategies
9.3. Product Mapping of Top 10 Player
9.4. Competitive Dashboard
9.5. Competitive Heatmap
9.6. Key developments

CHAPTER 10: COMPANY PROFILES
10.1 Abbott Laboratories
10.1.1 Company overview
10.1.2 Company snapshot
10.1.3 Operating business segments
10.1.4 Product portfolio
10.1.5 Business performance
10.1.6 Key strategic moves and developments
10.2 Agilent Technologies Inc.
10.2.1 Company overview
10.2.2 Company snapshot
10.2.3 Operating business segments
10.2.4 Product portfolio
10.2.5 Business performance
10.2.6 Key strategic moves and developments
10.3 Applied Spectral Imaging
10.3.1 Company overview
10.3.2 Company snapshot
10.3.3 Operating business segments
10.3.4 Product portfolio
10.3.5 Business performance
10.3.6 Key strategic moves and developments
10.4 Cyto Test Inc.
10.4.1 Company overview
10.4.2 Company snapshot
10.4.3 Operating business segments
10.4.4 Product portfolio
10.4.5 Business performance
10.4.6 Key strategic moves and developments
10.5 Danaher Corporation (Cephied)
10.5.1 Company overview
10.5.2 Company snapshot
10.5.3 Operating business segments
10.5.4 Product portfolio
10.5.5 Business performance
10.5.6 Key strategic moves and developments
10.6 Empire Genomics, LLC.
10.6.1 Company overview
10.6.2 Company snapshot
10.6.3 Operating business segments
10.6.4 Product portfolio
10.6.5 Business performance
10.6.6 Key strategic moves and developments
10.7 Genial Genetic Solutions Ltd.
10.7.1 Company overview
10.7.2 Company snapshot
10.7.3 Operating business segments
10.7.4 Product portfolio
10.7.5 Business performance
10.7.6 Key strategic moves and developments
10.8 Illumina, Inc.
10.8.1 Company overview
10.8.2 Company snapshot
10.8.3 Operating business segments
10.8.4 Product portfolio
10.8.5 Business performance
10.8.6 Key strategic moves and developments
10.9 PerkinElmer, Inc.
10.9.1 Company overview
10.9.2 Company snapshot
10.9.3 Operating business segments
10.9.4 Product portfolio
10.9.5 Business performance
10.9.6 Key strategic moves and developments
10.10 Sema4 Holdings Corp.
10.10.1 Company overview
10.10.2 Company snapshot
10.10.3 Operating business segments
10.10.4 Product portfolio
10.10.5 Business performance
10.10.6 Key strategic moves and developments
10.11 Sysmex Corporation (Oxford Gene Technology)
10.11.1 Company overview
10.11.2 Company snapshot
10.11.3 Operating business segments
10.11.4 Product portfolio
10.11.5 Business performance
10.11.6 Key strategic moves and developments
10.12 Thermo Fisher Scientific Inc.
10.12.1 Company overview
10.12.2 Company snapshot
10.12.3 Operating business segments
10.12.4 Product portfolio
10.12.5 Business performance
10.12.6 Key strategic moves and developments

Executive Summary

According to this report, titled, 'Molecular Cytogenetics Market,' the molecular cytogenetics market size was valued at $2.2 billion in 2021, and is estimated to reach $5.2 billion by 2031, growing at a CAGR of 8.7% from 2022 to 2031.

Molecular cytogenetics includes the chromosome biology and the use of molecular cytogenetic methods in biology and medicine. Molecular cytogenetics can help study the structural and functional organization of the nucleus and the chromosome of the cell, expression, and evolution of genes, genome variation in tumor genetics, and medical genetics. The common techniques involved in molecular cytogenetics include fluorescence in situ hybridization (FISH), comparative genomic hybridization (CGH), and array comparative genomic hybridization (aCGH).

According to the WHO, World Health Organization, genetic disorders and congenital abnormalities occur in about 2%-5% of all live births, and accounts for up to 30% of pediatric hospital admissions in the industrialized countries. Thus, the high prevalence and large economic burden of genetic disorders and cancer and rise in healthcare expenditure has led to the increase in the use of molecular cytogenetic products in the organizations such as clinical and research laboratories, academic research institutes, and pharmaceutical and biotechnology companies, contract research organization, and others.

Furthermore, factors such as the increase in approval rate of the diagnostic procedures related to the molecular cytogenetics in developing regions, high incidence of congenital abnormalities, growing focus of government organizations on providing funding for research, and increasing awareness about the diagnosis and treatment options accelerate the growth of the molecular cytogenetics market trends. The molecular cytogenetics market growth is also anticipated to be facilitated by the introduction of numerous cutting-edge diagnostic technologies by the biotechnology companies, an increase in the demand for accurate diagnosis of serious cancer diseases, and the availability of skilled personnel and pathologist with the necessary training in developed countries.

However, the molecular cytogenetics industry is expected to be significantly constrained in the near future by factors such as high cost of the associated equipment’s and technologies and with the products.

According to the product, consumables segment was the largest segment in the 2021, owing to the increase in the usage of the molecular cytogenetics products in clinical and research laboratories and also due to the rise in the usage of media and reagents. On the other hand, the software and services segment is expected to grow at a fastest CAGR during the forecast period owing to the technological advances in the medical field that combines the information technology and healthcare sector.

By technique, the comparative genomic hybridization holds a dominant portion in the global molecular cytogenetics market in 2021 and is expected to grow at the fastest rate of CAGR during the forecast period, owing to the advantages that the comparative genomic hybridization (CGH) technique offers over other conventional techniques which includes high resolution than others and due to its wide application in the cancer studies.

By application, the genetic disorders segment accounts for the largest share of the global market in 2021, due effective and high usage of molecular cytogenetic techniques for in-depth studies of genetic disorders such as cancer and its management. Furthermore, the personalized medicines segment is expected to grow at the fastest CAGR during the forecast period, due to the wide application of molecular cytogenetics in drug discovery and development, and biomarker discovery.

By end user, the clinical and research laboratories owned the largest share of the market in 2021, because of the adoption for advanced and precise diagnostic tools by pathologist and researchers in the clinical and research laboratories and rise in the number of the pathological testing and is expected to grow at the highest CAGR during the forecast period.

Region wise, North America acquired a major molecular cytogenetics market share, owing to the presence of an effective regulatory framework for the regulation of genetic tests and acquisitions and collaborations by the key market players in this region. However, Asia-Pacific is expected to witness the highest CAGR during the forecast period due to emerging markets in Asia and transition from fish to array-based techniques in this region.

KEY FINDINGS OF THE STUDY

By product, the consumables segment was the highest contributor to the market in 2021.

By technique, the comparative genomic hybridization segment was the highest contributor to the market in 2021, and is expected to continue this trend during the forecast period.

By application, the genetic disorders segment was the highest contributor to the market in 2021, and on the other hand the personalized medicines segment is expected to grow with a highest CAGR during the forecast period.

Depending on end user, the clinical and research laboratories segment was highest contributor in 2021 and is expected to grow at the fastest CAGR during the forecast period.

Region wise, North America holds the largest revenue share in 2021, whereas Asia-Pacific is anticipated to grow at the highest CAGR during the forecast period.

Companies Mentioned

• Abbott Laboratories
• Agilent Technologies Inc.
• Applied Spectral Imaging
• Cyto Test Inc.
• Danaher Corporation (Cephied)
• Empire Genomics, LLC.
• Genial Genetic Solutions Ltd.
• Illumina, Inc.
• Perkinelmer, Inc.
• Sema4 Holdings Corp.
• Sysmex Corporation (Oxford Gene Technology)
• Thermo Fisher Scientific Inc.

Methodology

The analyst offers exhaustive research and analysis based on a wide variety of factual inputs, which largely include interviews with industry participants, reliable statistics, and regional intelligence. The in-house industry experts play an instrumental role in designing analytic tools and models, tailored to the requirements of a particular industry segment. The primary research efforts include reaching out participants through mail, tele-conversations, referrals, professional networks, and face-to-face interactions.

They are also in professional corporate relations with various companies that allow them greater flexibility for reaching out to industry participants and commentators for interviews and discussions.

They also refer to a broad array of industry sources for their secondary research, which typically include; however, not limited to:

• Company SEC filings, annual reports, company websites, broker & financial reports, and investor presentations for competitive scenario and shape of the industry
• Scientific and technical writings for product information and related preemptions
• Regional government and statistical databases for macro analysis
• Authentic news articles and other related releases for market evaluation
• Internal and external proprietary databases, key market indicators, and relevant press releases for market estimates and forecast

Furthermore, the accuracy of the data will be analyzed and validated by conducting additional primaries with various industry experts and KOLs. They also provide robust post-sales support to clients.